MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.
Company profile
Ticker
MYMD
Exchange
Website
CEO
Howard Yeaton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Akers Biosciences Inc, Akers Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Akers Acquisition Sub, Inc. • Bout Time Marketing Corporation • MyMD Pharmaceuticals (Florida), Inc. • XYZ Merger Sub Inc. ...
MYMD stock data
Latest filings (excl ownership)
8-K
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
18 Nov 22
8-K
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
DEFA14A
Additional proxy soliciting materials
26 Oct 22
DEF 14A
Definitive proxy
26 Oct 22
8-K
Efficacy data anticipated in Q4 of 2022
20 Sep 22
8-K
Mymd Pharmaceuticals Receives Grant from European
31 Aug 22
D
$7.41M in options / securities to be acquired, 8 investors
30 Aug 22
8-K
Entry into a Material Definitive Agreement
17 Aug 22
424B5
Prospectus supplement for primary offering
17 Aug 22
Latest ownership filings
SC 13D
DUFFEY SAMUEL S
8 Sep 22
SC 13G/A
Iroquois Capital Management, LLC
23 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
MAINFIELD ENTERPRISES INC
11 Jan 22
4
Joshua Silverman
29 Nov 21
4
Paul Rivard
24 Nov 21
4
Adam Kaplin
15 Oct 21
4
Christopher C Schreiber
15 Oct 21
4
Billy Joe White
15 Oct 21
4
Jude Uzonwanne
15 Oct 21
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 309.93 k | 309.93 k | 309.93 k | 309.93 k | 309.93 k | 309.93 k |
| Cash burn (monthly) | 268.42 k | 88.76 k | 1.24 mm | 1.23 mm | 1.36 mm | 1.24 mm |
| Cash used (since last report) | 514.03 k | 169.97 k | 2.37 mm | 2.35 mm | 2.61 mm | 2.37 mm |
| Cash remaining | -204.10 k | 139.95 k | -2.06 mm | -2.04 mm | -2.30 mm | -2.06 mm |
| Runway (months of cash) | -0.8 | 1.6 | -1.7 | -1.7 | -1.7 | -1.7 |
Institutional ownership, Q3 2022
20.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 43 |
| Opened positions | 15 |
| Closed positions | 11 |
| Increased positions | 8 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 22.66 mm |
| Total shares | 8.05 mm |
| Total puts | 82.10 k |
| Total calls | 133.00 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Caroline C Williams | 3.75 mm | $9.26 mm |
| Vanguard | 1.46 mm | $3.80 mm |
| Mirae Asset Global Investments | 638.58 k | $1.67 mm |
| Intracoastal Capital | 364.96 k | $2.21 mm |
| MS Morgan Stanley | 285.46 k | $745.00 k |
| Geode Capital Management | 273.05 k | $712.00 k |
| Iroquois Capital Management | 260.37 k | $1.58 mm |
| BLK Blackrock | 195.46 k | $510.00 k |
| Shay Capital | 139.99 k | $365.00 k |
| M Holdings Securities | 70.91 k | $185.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 Nov 21 | Silverman Joshua | Common Stock | Buy | Acquire P | No | No | 7.5543 | 5,000 | 37.77 k | 88,775 |
| 24 Nov 21 | Silverman Joshua | Common Stock | Buy | Acquire P | No | No | 7.0937 | 3,266 | 23.17 k | 83,775 |
| 24 Nov 21 | Silverman Joshua | Common Stock | Buy | Acquire P | No | No | 6.2991 | 6,734 | 42.42 k | 80,509 |
| 23 Nov 21 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 6.03 | 15,000 | 90.45 k | 215,000 |
| 14 Oct 21 | Christopher C Chapman JR | RSU Common Stock | Grant | Acquire A | No | No | 0 | 600,000 | 0.00 | 600,000 |
| 14 Oct 21 | Paul Rivard | RSU Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 200,000 |
| 14 Oct 21 | Craig Eagle | RSU Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 150,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
23 Nov 22
MyMD Pharmaceuticals Announces Publication Of Phase 1 Data For Oral TNF-alpha Inhibitor MYMD-1 In Peer-Reviewed Journal Drug Research
14 Nov 22
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
4 Oct 22
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
27 Sep 22
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
26 Sep 22